Generic Medicine Info
Should be taken with food.
Systemic fungal infections; systemic infection unless treated with specific anti-infective, cerebral malaria. Concomitant administration with live or live attenuated vaccines (particularly immunosuppressive doses).
Special Precautions
Patient with systemic sclerosis; gastrointestinal disease (e.g. active or latent peptic ulcer, non-specific ulcerative colitis, diverticulitis, fresh intestinal anastomoses), hypertension, CHF, recent MI, myasthenia gravis, epilepsy or history of seizure disorders, psychiatric disorders, diabetes mellitus, thyroid disease, cirrhosis, uraemia, osteoporosis or at risk of osteoporosis (e.g. postmenopausal women), osteomalacia, corneal ulcers and injuries, cataract, glaucoma, acute viral infections (e.g. chickenpox, measles, herpetic keratitis), history of ocular herpes simplex, systemic mycoses and parasitosis (e.g. nematodes, Strongyloides infestation), tuberculosis, poliomyelitis, lymphadenitis following BCG inoculation, previous steroid myopathy. Patient subjected to stress conditions (e.g. trauma, infection, surgery). Avoid abrupt withdrawal. Renal and hepatic impairment. Children and elderly. Pregnancy and lactation. Monitoring Parameters Monitor blood pressure, serum creatinine, serum glucose, Hb, and electrolytes; occult blood loss, intraocular pressure (>6 weeks therapy), bone mineral density, weight; growth and development in children. Perform eye examination periodically during treatment; chest x-ray at regular intervals (prolonged use). Assess for signs and symptoms of HPA axis suppression, infection, or ocular changes.
Adverse Reactions
Significant: Adrenal suppression (e.g. hypercortisolism, suppression of hypothalamic-pituitary-adrenal [HPA] axis), left ventricular free wall rupture, visual disturbances (e.g. cataract, open-angle glaucoma, increased intraocular pressure, central serous chorioretinopathy), corneal perforation, osteoporosis, growth suppression in children, Kaposi sarcoma (prolonged use), acute myopathy, immunosuppression, convulsions, psychiatric disturbances (e.g. insomnia, euphoria, mood swings, personality changes, severe depression, frank psychotic manifestations), withdrawal symptoms (e.g. muscle weakness, hypotension, hypoglycaemia, muscle and joint pain). Rarely, anaphylactoid reactions. Blood and lymphatic system disorders: Moderate leucocytosis, lymphopenia, eosinopenia, polycythaemia. Cardiac disorders: Arrhythmia. Ear and labyrinth disorders: Vertigo. Eye disorders: Blurred vision. Gastrointestinal disorders: Nausea, vomiting, diarrhoea, constipation, abdominal distension, gastric irritation, ulcerative oesophagitis, pancreatitis, peptic ulceration with perforation and haemorrhage. General disorders and administration site conditions: Impaired wound healing. Investigations: Increased AST/ALT, weight gain, EEG abnormalities, negative nitrogen balance, reduced glucose tolerance. Metabolism and nutrition disorders: Cushing's syndrome, anorexia, sodium and water retention, hypokalaemia, hypokalaemic alkalosis, hypercholesterolaemia, hypertriglyceridaemia, carbohydrate intolerance. Musculoskeletal and connective tissue disorders: Muscle atrophy, vertebral compression fractures. Nervous system disorders: Headache, restlessness. Reproductive system and breast disorders: Menstrual disorders. Skin and subcutaneous tissue disorders: Hirsutism, acneiform eruption, thinning of skin, purpura, increased sweating, striae rubrae, telangiectasia, petechiae, ecchymoses. Vascular disorders: Hypertension.
Potentially Fatal: Acute adrenal insufficiency, scleroderma renal crisis.
Drug Interactions
May reduce the hypoglycaemic effects of antidiabetics. Increased risk of arrhythmias with digitalis glycosides. May either enhance or reduce the efficacy of coumarin anticoagulants. Increased risk of gastrointestinal ulceration or haemorrhage with NSAIDs, salicylates. May cause additional increased intraocular pressure with anticholinergic agents (e.g. atropine). Decreased serum concentrations of praziquantel, isoniazid. May reduce the therapeutic effects of somatropin. Increased risk of myopathies or cardiomyopathies with antimalarials (e.g. chloroquine, hydroxychloroquine, mefloquine). Efficacy may be potentiated by oestrogens. May reduce the therapeutic efficacy with mifepristone, CYP3A4 inducers (e.g. phenobarbital, rifampicin, primidone, carbamazepine). May decrease the clearance and increase serum concentration with CYP3A4 inhibitors (e.g. ketoconazole, ritonavir, erythromycin). Increased serum levels of ciclosporin. Increased risk of hypokalaemia with K-depleting agents (e.g. amphotericin B, diuretics). Decreased absorption with Al- and Mg-containing antacids. Increased risk of tendon rupture with fluoroquinolones (e.g. ciprofloxacin, levofloxacin).
ATC Classification
A07EA03 - prednisone ; Belongs to the class of corticosteroids acting locally. Used in the treatment of intestinal inflammation.
H02AB07 - prednisone ; Belongs to the class of glucocorticoids. Used in systemic corticosteroid preparations.
Disclaimer: This information is independently developed by CIMS based on prednisone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in